---
title: "QTREX Quantum (QTEX) prices $10,000,000 registered direct offering at $0.90 a share"
url: "https://aibio.space/news/qtrex-quantum-qtex-prices-10-000-000-registered-direct-offering-0-90/"
event_date: "2026-08-20"
date_published: "2026-11-08"
description: "QTREX Quantum Ltd. agreed on August 20, 2026 to sell 11,111,111 ordinary shares at $0.90 each, for gross proceeds of $10,000,000, with A.G.P./Alliance Global Partners as placement agent."
---

# QTREX Quantum (QTEX) prices $10,000,000 registered direct offering at $0.90 a share

QTREX Quantum Ltd. (Nasdaq: QTEX) agreed on August 20, 2026 to sell 11,111,111 ordinary shares at $0.90 each in a registered direct offering to institutional investors. The prospectus supplement puts the total at $10,000,000 before the placement agent's fee. The terms are set out in a [prospectus supplement dated August 20, 2026](https://www.sec.gov/Archives/edgar/data/1837493/000118518526003663/qtrex424b5082026.htm) and in a [Form 6-K dated August 20, 2026](https://www.sec.gov/Archives/edgar/data/1837493/000118518526003653/qtrex6k082026.htm).

Why is this important: The company expects net proceeds of about $9.1 million after expenses. The prospectus shows $3,159 thousand of cash and cash equivalents as of December 31, 2025, so the new money is large next to that figure. The $0.90 price sits below the $1.12 last sale on August 19, 2026, and buyers take an immediate dilution of $0.54 per share in net tangible book value.

Dagi Ben-Noon, the chief executive officer, signed the company's August 20, 2026 Form 6-K. The prospectus names A.G.P./Alliance Global Partners as the exclusive placement agent, with a fee of 7.0% of the gross proceeds. In our view, the share count rose from 35,949,247 on December 31, 2025 to 55,963,934 on August 19, 2026, before this sale, and the pattern suggests the company is funding itself with stock. The price of $0.90 is also below the last sale.

## What the offering costs shareholders

The prospectus supplement lists placement agent fees of $700,000 and proceeds of $9,300,000 before expenses. It puts the estimated net proceeds at about $9.1 million, which the company says it will use for working capital and general corporate purposes. The placement agency agreement also requires the company to reimburse the agent's legal and other expenses, up to $50,000, and to pay $12,500 in non-accountable expenses. The company agreed not to issue more shares, or file another registration statement, for 30 days after closing, subject to exceptions, according to the 6-K.

The prospectus says the placement agent agreed to use reasonable best efforts and was not required to buy or sell any specific number of shares. The capitalization table in the same prospectus lists two earlier 2026 transactions as pro forma adjustments. One is a sale of $4.3 million net under a sales agreement with A.G.P./Alliance Global Partners as of February 5, 2026. The other is a private placement that produced $9.1 million of net proceeds, for 3,895,000 ordinary shares and 2,771,667 ordinary shares issuable on exercise of pre-funded warrants. The prospectus warns that future issuances could result in further dilution to shareholders.

## The business and the lead technology

QTREX Quantum describes itself as a technology company focused on the research, development, manufacturing and commercialization of advanced connectivity solutions for the quantum computing industry. The prospectus names the cryogenic interconnect as the hardware constraint it targets. That is the wiring that carries control and readout signals between room-temperature electronics and the qubits inside a dilution refrigerator. In April 2026 the company acquired an Additively Manufactured Electronics platform from Nano Dimension Technologies Ltd.

The company was named Inspira Technologies Oxy B.H.N. Ltd until May 10, 2026, when it changed its name to QTREX Quantum Ltd. It also runs a separate medical platform built on the INSPIRA ART100, an FDA-cleared advanced life-support system. The prospectus describes no clinical trial for either business, and says the company is actively seeking to monetize the medical business through one or more strategic transactions.

## What comes next

The offering was expected to close on or about August 21, 2026, subject to customary closing conditions. The investors buy directly from the company under a securities purchase agreement dated August 20, 2026. The shares trade on the Nasdaq Capital Market under QTEX. The company says there can be no assurance that its talks about the medical business will produce a transaction.

The prospectus warns that future issuances or sales of ordinary shares may cause the trading price to decline. It also says that if the company fails to meet all applicable Nasdaq Capital Market requirements, Nasdaq could delist the ordinary shares, which could adversely affect the market for them.

Sources

- https://www.sec.gov/Archives/edgar/data/1837493/000118518526003663/qtrex424b5082026.htm
- https://www.sec.gov/Archives/edgar/data/1837493/000118518526003653/qtrex6k082026.htm
